NGM707

Phase 2Small molecule

NGM707 is one of 4 small molecule programs targeting Advanced or Metastatic Solid Tumor Malignancies. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced or Metastatic Solid Tumor MalignanciesActive, not recruiting

Advanced or Metastatic Solid Tumor MalignanciesPhase 2

Active, not recruiting

Competition

Competitive Landscape

7 competitors in Advanced or Metastatic Solid Tumor Malignancies

#DrugCompanyPhaseTrials

NP-G2-044

NNovita Pharmaceuticals, Inc.

Phase 2

1 2

NGM707

NNGM Biopharmaceuticals, Inc

Phase 2

1 3

Anti-PD-1 Therapy

NNovita Pharmaceuticals, Inc.

Phase 2

1 4

Chemotherapy Drug

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Advanced or Metastatic Solid Tumor Malignancies1 trial

Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

Active, not recruiting·NNGM Biopharmaceuticals, Inc·Phase 1/2·NCT04913337·179 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for NGM707. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NGM707 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NGM707. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — NGM Biopharmaceuticals, Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNGM Biopharmaceuticals, Inc

NGM707

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Advanced or Metastatic Solid Tumor Malignancies1 trial

References

Drug Info

Quick Facts

Related News